[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

FI942622A0 - Transformoivan kasvutekijän beta inhibiitio solun ulkopuolisen matriisin akkumulaation estämiseksi - Google Patents

Transformoivan kasvutekijän beta inhibiitio solun ulkopuolisen matriisin akkumulaation estämiseksi

Info

Publication number
FI942622A0
FI942622A0 FI942622A FI942622A FI942622A0 FI 942622 A0 FI942622 A0 FI 942622A0 FI 942622 A FI942622 A FI 942622A FI 942622 A FI942622 A FI 942622A FI 942622 A0 FI942622 A0 FI 942622A0
Authority
FI
Finland
Prior art keywords
growth factor
fibrosis
extracellular matrix
transforming growth
factor beta
Prior art date
Application number
FI942622A
Other languages
English (en)
Swedish (sv)
Other versions
FI942622A (fi
Inventor
Erkki I Ruoslahti
Wayne A Border
Original Assignee
Jolla Cancer Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jolla Cancer Res Found filed Critical Jolla Cancer Res Found
Publication of FI942622A0 publication Critical patent/FI942622A0/fi
Publication of FI942622A publication Critical patent/FI942622A/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
FI942622A 1991-12-04 1994-06-03 Transformoivan kasvutekijän beta inhibiitio solun ulkopuolisen matriisin akkumulaation estämiseksi FI942622A (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80328591A 1991-12-04 1991-12-04
PCT/US1992/010550 WO1993010808A1 (en) 1991-12-04 1992-12-04 INHIBITING TRANSFORMING GROWTH FACTOR β TO PREVENT ACCUMULATION OF EXTRACELLULAR MATRIX

Publications (2)

Publication Number Publication Date
FI942622A0 true FI942622A0 (fi) 1994-06-03
FI942622A FI942622A (fi) 1994-07-27

Family

ID=25186123

Family Applications (1)

Application Number Title Priority Date Filing Date
FI942622A FI942622A (fi) 1991-12-04 1994-06-03 Transformoivan kasvutekijän beta inhibiitio solun ulkopuolisen matriisin akkumulaation estämiseksi

Country Status (10)

Country Link
EP (1) EP0616536B1 (fi)
JP (2) JP3854307B2 (fi)
AT (1) ATE177644T1 (fi)
AU (2) AU670770B2 (fi)
CA (1) CA2124591A1 (fi)
DE (1) DE69228700T2 (fi)
DK (1) DK0616536T3 (fi)
FI (1) FI942622A (fi)
NO (1) NO942072L (fi)
WO (1) WO1993010808A1 (fi)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994026303A1 (en) * 1993-05-13 1994-11-24 Neorx Corporation Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells
US5453492A (en) * 1993-07-28 1995-09-26 La Jolla Cancer Research Foundation 60 kDa transforming growth factor-β-binding protein and its use to detect or purify TGF-β
EP0735895B1 (en) * 1993-11-19 2006-01-18 The University Of Sydney A method for preventing or controlling cataract
ES2140670T3 (es) * 1994-03-29 2000-03-01 Univ Manchester Cicatrizacion de heridas.
US5824655A (en) * 1995-02-15 1998-10-20 The University Of Utah Anti-transforming growth factor-β gene therapy
DE19613691A1 (de) * 1996-04-05 1997-10-09 Boehringer Ingelheim Int Arzneimittel für die Behandlung von Tumorerkrankungen
WO1999034823A2 (en) * 1998-01-09 1999-07-15 University Of Utah METHODS FOR PREVENTING AND TREATING FIBROTIC DISEASES RESULTING FROM ACCUMULATION OF EXCESS EXTRACELLULAR MATRIX INDUCED BY TGFβ USING RENIN INHIBITORS
AU2008200019B2 (en) * 1999-01-05 2009-10-08 American National Red Cross Methods for treating conditions associated with the accumulation of excess extracellular matrix
EP2130532A1 (en) 1999-01-05 2009-12-09 University of Utah Research Foundation Method for treating conditions associated with the accumulation of excess extracellular matrix
US7763580B2 (en) 1999-01-05 2010-07-27 University Of Utah Research Foundation Methods for treating conditions associated with the accumulation of excess extracellular matrix
US7612038B2 (en) * 1999-11-18 2009-11-03 Brown University Biglycan and related therapeutics and methods of use
US6864236B1 (en) * 1999-11-18 2005-03-08 Brown University Research Foundation Biglycan and related therapeutics and methods of use
GB0102673D0 (en) * 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
ATE420654T1 (de) 2001-08-15 2009-01-15 Univ Brown Res Found Behandlung von muskeldystrophien und verwandter erkrankungen
CA2473829A1 (en) * 2002-01-22 2003-07-31 Genzyme Corporation Use of tgf-.beta. antagonists to treat or to prevent chronic transplant rejection
WO2004075917A1 (ja) * 2003-02-28 2004-09-10 Toudai Tlo, Ltd. 器官または組織の線維化抑制剤
EP2862867A3 (en) 2005-10-25 2015-08-05 The Johns Hopkins University Methods and compositions for the treatment of Marfan syndrome and associated disorders
WO2007108992A2 (en) 2006-03-13 2007-09-27 The Johns Hopkins University Augmentation of endothelial thromboresistance
EP1983345A1 (en) * 2007-04-17 2008-10-22 Roche Diagnostics GmbH Means and method for assessing the risk of a cardiac intervention in patients suffering from a stable coronary heart disease based on GDF-15
DK3117709T3 (en) 2010-03-12 2018-11-26 Genzyme Corp COMBINATION THERAPY FOR TREATMENT OF BREAST CANCER
ES2691443T3 (es) 2010-05-17 2018-11-27 Brown University Mutantes de biglicano y agentes terapéuticos relacionados y métodos de uso
US8956868B2 (en) 2010-12-27 2015-02-17 Lsip, Llc Induced pluripotent stem cells produced with a connexin inhibitor and a TGF-β signaling inhibitor
EP3026432A3 (en) 2010-12-27 2016-07-27 Brown University Method for predicting patient's response to biglycan treatment
KR102577578B1 (ko) 2011-06-03 2023-09-11 조마 테크놀로지 리미티드 Tgf-베타에 특이적인 항체
WO2013100208A1 (ja) 2011-12-28 2013-07-04 京都府公立大学法人 角膜内皮細胞の培養正常化
EP3064222B1 (en) 2013-10-31 2020-10-21 Kyoto Prefectural Public University Corporation Therapeutic drug comprising tgf-beta signal inhibitor for diseases related to endoplasmic reticulum cell death in corneal endothelium
US10882903B2 (en) 2015-05-18 2021-01-05 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods and compositions for treating an alphavirus infection
WO2017223268A1 (en) * 2016-06-22 2017-12-28 Yale University COMPOSITIONS AND METHODS OF RESENSITIZING CELLS TO BROMODOMAIN AND EXTRATERMINAL DOMAIN PROTEIN INHIBITORS (BETi)
JP7109039B2 (ja) 2016-07-07 2022-07-29 国立大学法人千葉大学 抗線維症剤およびリン酸化Ｓｍａｄ核内移行阻害剤
KR102141125B1 (ko) * 2018-01-22 2020-08-05 고려대학교 산학협력단 비글리칸을 유효성분으로 함유하는 당뇨병 예방 또는 치료용 약학 조성물
WO2019143219A1 (ko) * 2018-01-22 2019-07-25 고려대학교 산학협력단 비글리칸을 유효성분으로 함유하는 당뇨병 예방 또는 치료용 약학 조성물
FR3090320B1 (fr) * 2018-12-19 2023-03-03 Karim Bouzakri Utilisation de la decorine dans le traitement du diabete
US12048731B2 (en) * 2019-04-11 2024-07-30 Daegu Gyeongbuk Institute Of Science And Technology Appetite suppression with pharmaceutical compositions containing biglycan as an active ingredient

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991004748A1 (en) * 1989-09-29 1991-04-18 La Jolla Cancer Research Foundation INHIBITING TRANSFORMING GROWTH FACTOR β TO PREVENT ACCUMULATION OF EXTRACELLULAR MATRIX
WO1991010727A1 (en) * 1990-01-22 1991-07-25 La Jolla Cancer Research Foundation Inhibitors of cell regulatory factors

Also Published As

Publication number Publication date
EP0616536A1 (en) 1994-09-28
EP0616536B1 (en) 1999-03-17
WO1993010808A1 (en) 1993-06-10
NO942072L (no) 1994-08-03
JPH07504650A (ja) 1995-05-25
ATE177644T1 (de) 1999-04-15
FI942622A (fi) 1994-07-27
DE69228700T2 (de) 1999-09-09
AU7051896A (en) 1997-01-16
AU670770B2 (en) 1996-08-01
DE69228700D1 (de) 1999-04-22
CA2124591A1 (en) 1993-06-10
JP3854307B2 (ja) 2006-12-06
JP2004043507A (ja) 2004-02-12
AU3242993A (en) 1993-06-28
DK0616536T3 (da) 1999-10-11
NO942072D0 (no) 1994-06-03

Similar Documents

Publication Publication Date Title
FI942622A0 (fi) Transformoivan kasvutekijän beta inhibiitio solun ulkopuolisen matriisin akkumulaation estämiseksi
ATE193541T1 (de) Insulinotropes hormon
Roberge et al. Regulation of intestinal proglucagon-derived peptide secretion by glucose-dependent insulinotropic peptide in a novel enteroendocrine loop
El-sherif et al. Quinidine-induced long QTU interval and torsade de pointes: role of bradycardia-dependent early afterdepolarizations
DE60023492D1 (de) Glucagon antagonisten/inverse agonisten
EP1123129A4 (en) SYSTEMS AND COMPOUNDS FOR ADMINISTRATION OF MEDICINE IN INTERSTITIAL REGIONS OF MYOCARD
NO921119L (no) Inhibering av transformerende vekstfaktor beta for aa forhindre akkumulering av ekstracellulaer matriks
RU94013439A (ru) Гетероциклические соединения, способ их получения, фармацевтическая композиция и способ лечения
DK0964692T3 (da) Anvendelse af GLP 1 eller analoger til behandling af myocardialt infarkt
ES2054995T3 (es) Nuevos derivados del acido benzoico y acido fenilacetico, su obtencion y empleo como medicamentos.
IT8619684A0 (it) Preparato di acido ialuronico chimicamente modificato e metodo per recuperarlo da tessuti animali.
DE60000288D1 (de) Monodisperse formulierungen, die hexamere acylierte insulinanaloge enthalten
AU2020200934A1 (en) Long-acting adrenomedullin derivative
Doi et al. Vascular endothelial growth factor suppresses C-type natriuretic peptide secretion
NO166939C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive carboxylsyrederivater.
DK47089A (da) Middel med oedelaeggende virkning paa maligne tumorer, fremgangsmaade til fremstilling af saadanne midler og anvendelse af disse til terapeutisk behandling af cancer
Louis et al. A diabetogenic polypeptide from bovine adenohypophysis similar to that excreted in lipoatrophic diabetes
Sassolas et al. Nocturnal continuous infusion of growth hormone (GH)-releasing hormone results in a dose-dependent accentuation of episodic GH secretion in normal men
LV11987A (lv) Aptaukosanas noversanas vai arstesanas metode
Plack et al. Complete heart block developing during aortic valvuloplasty
WO1996002269A1 (en) Therapeutic method and compounds of use therein
UA72871C2 (uk) Засіб для лікування та профілактики цукрового діабету та спосіб лікування
White Hormones of the Adenohypophysis
Tasman-Jones Chairman's Summary
Levack The calcinogenic principles of Trisetum flavescens

Legal Events

Date Code Title Description
FD Application lapsed